Trastuzumab targeted therapy for breast cancer patients with HER2 overexpression or amplification (HER2+) yields a favorable effect (Swain et al., 2023), However, there are still some patients who exhibit no response or develop clinical drug resistance (Gaynor et al., 2023; Leemasawat et al., 2024). This evidence concerns the gene ERBB2 and breast cancer.